Abstract: This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for use in the invention may comprise an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to the use of a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. The invention also includes the use of various medicaments in the biomaterial formulations to enhance the treatment of the affected area of the body.

Abstract: Provided are injectable, hyaluronic acid-based hydrogel compositions including conjugated vitamins.

Abstract: The present invention provides dyes and labeled reagents that may be used in the detection or quantification of desirable target molecules, such as proteins, nucleic acids and cellular organelles. Dyes are provided that may be used free in solution where the binding of the dye to the target molecule provides signal generation. Dyes provided in this invention can comprise reactive groups that may be used to attach the dyes to probes that will bind to desirable target molecules. The novel dyes of the present invention have been substituted with specific groups to provide beneficial properties.

Abstract: A method of preparing genipin-rich materials from the fruit of Genipa americana fruit for their use as a cross-linking agent and as a raw material to produce colors is disclosed. The genipin-rich materials can be used in a broad range of applications including personal care, cosmetics, dietary supplements, packaging, textiles, beverages, foodstuffs, drugs, and animal feeds.

Abstract: The present invention synthetic oligo-?-(1?6)-glucosamine structures and a methodology which essentially allows for the synthesis of any oligo-?-(1?6)-glucosamine species having a definite number of monosaccharide units, including a set pattern of acetylated and non-acetylated residues. The invention further provides antibodies to these synthetic oligo-?-(1?6)-glucosamines as well as compositions thereof and methods for treating and preventing infections caused by bacteria expressing poly-?-(1?6)-glucosamines, such as Staphylococcus aureus.

Abstract: A method for adhering a medical device to biological tissue includes adhering an adhesive composition having a plurality of reactive members of a specific binding pair to tissue which has a plurality of complementary reactive members of the specific binding pair via click chemistry.

Abstract: Disclosed are saccharide and phosphocholine derivatives. The derivatives include azide and alkyne derivatives which form one end of a variable length carbon chain. The opposite end of the variable length carbon chain is covalently linked to the saccharide or phosphocholine. The saccharide may be, for instance, a maltoside. The alkyne and azide derivatives of the saccharides and phosphocholine may be reacted together to form amphiphilic molecules useful in cellular membrane studies and applications. By adjusting the length of the carbon chain, the biochemical and biophysical properties of the resultant 1,4-disubstituted 1,2,3-triazole compounds may be custom tailored for the intended application. Resultant molecules may form micelles, bicelle, lipid bilayers and other like structures useful in the isolation and purification of membrane bound or membrane associated proteins and biochemical components.

Abstract: The present invention relates to a process for the synthesis of the Factor Xa anticoagulent Fondaparinux and related compounds. The invention relates, in addition, to efficient and scalable processes for the synthesis of various intermediates useful in the synthesis of Fondaparinux and related compounds.

Abstract: The invention provides a polymer support characterized in that the polymer is 6-amino 6-deoxy chitosan. Metal-immobilized 6-amino 6-deoxy chitosan is further provided, more particularly including one of Pd, Pt, Ru, Rh Ir, Os, Mn, Ni, Co and Fe in all their possible oxidation states complexed to 6-amino 6-deoxy chitosan through a Schiff-base ligand.

Abstract: Provided are various compounds comprising the formula Also provided are fluorescent dyes comprising the above compound. Additionally, a fluorescence energy transfer system is provided that comprises the above-described fluorescent dye and a second dye, wherein the second dye is capable of energy transfer with the fluorescent dye. Further provided is a kit for labeling a target molecule, where the kit comprises the above-described fluorescent dye with additional reagents useful for labeling the target molecule. Additionally provided is a target molecule labeled with the above-described fluorescent dye. A method of labeling a target molecule is also provided. The method comprises contacting reactive group Z of the above-described fluorescent dye with the target molecule such that reactive group Z reacts with the target molecule to form a covalent bond between reactive group Z and the target molecule. Also, another method of labeling a target molecule is provided.

Abstract: A cationized hyaluronic acid and/or a salt thereof includes a quaternary ammonium group-containing group, and has a degree of cationization of 0.15 to 0.6.

Abstract: Described herein is the synthesis of alkylated and semi-synthetic glycosaminoglycosan ethers, referred to herein as “SAGEs.” The synthesis of sulfated alkylated SAGEs is also described. The compounds described herein are useful in a number of applications including wound healing, drug delivery, and the treatment of a number of inflammatory diseases and skin disorders.

Abstract: Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide.

Abstract: The present invention provides multisignal labeling reagents and these are useful in a number of biochemical applications, including the manufacture of biomolecular probes and their use in detecting or amplifying analyte-specific moieties.

Abstract: The present invention provides multisignal labeling reagents and these are useful in a number of biochemical applications, including the manufacture of biomolecular probes and their use in detecting or amplifying analyte-specific moieties.

Abstract: The present invention provides multisignal labeling reagents and these are useful in a number of biochemical applications, including the manufacture of biomolecular probes and their use in detecting or amplifying analyte-specific moieties.

Abstract: A binder comprising a polymeric binder comprising the products of a carbohydrate reactant and nucleophile is disclosed. The binder is useful for consolidating loosely assembled matter, such as fibers. Fibrous products comprising fibers in contact with a carbohydrate reactant and a nucleophile are also disclosed. The binder composition may be cured to yield a fibrous product comprising fibers bound by a cross-linked polymer. Further disclosed are methods for binding fibers with the carbohydrate reactant and polyamine based binder.

Abstract: The present invention provides dyes, reactive dyes and labeled reagents that may be used in the detection or quantification of desirable target molecules, such as proteins and nucleic acids. Dyes are provided that may be used free in solution where the binding of the dye to the target molecule provides signal generation. Dyes are also provided that comprise reactive groups that may be used to attach the dyes to probes that will bind to desirable target molecules. The novel dyes of the present invention have been modified by the addition of charged and polar groups to provide beneficial properties.

Abstract: This invention related to a cationically and hydrophilically modified polygalactomannan having repeating units with an average D-mannosyl to D-galactosyl residue ratio of at least 5 to 1 and to compositions containing the same. A portion of the hydrogen atoms of hydroxyl groups situated on the mannosyl and galactosyl residues of the galactomannan are replaced with a hydrophilic and a cationic substituent.

Abstract: A low-molecular-weight hyaluronic acid and/or its salt has an average molecular weight of 5000 to 20,000, and has a molecular weight distribution in which the proportion of components having a molecular weight of 10,000 or less is 40 wt % or more and the proportion of components having a molecular weight of 50,000 or more is 5 wt % or less.

Abstract: The present invention relates to novel silyl-derivatives of polysaccharides and their salts, the processes for their preparation and their use in cosmetic/pharmaceutical field.

Abstract: The disclosure provides granular forms of porous biomaterials and methods for forming and applying these biomaterials, including uses to promote vascularization and tissue ingrowth.

Abstract: A drug-introduced photo-crosslinked hyaluronic acid derived gel which is a photo-crosslinked hyaluronic acid gel into which a drug is introduced through a covalent bond, and has characteristics that are capable of extruding from an injection device. The drug-introduced photo-cross-linked hyaluronic acid derived gel is capable of extruding, for example, by an injection needle of 20 to 25 gauge with a pressure of 0.5 to 5 kg/cm2.

Abstract: Compositions comprising a milk-derived oligosaccharide such as trifucosyl(1,2-1,2-1,3)-lacto-N-octoase (TFiLNO) and uses thereof for inhibiting invasion of gastrointestinal pathogen into intestinal epithelial cells or for treating an infectious disease (e.g., a disease caused by a gastrointestinal pathogen such as an ETEC) or an inflammatory diseases such as inflammatory bowel disease.

Abstract: A sugar derivative derived from Aphanothece sacrum as a freshwater blue-green alga, having a mean molecular weight of 2,000,000 or more and a repeat structure of a sugar chain unit where a sugar constituent of a hexose structure and a sugar constituent of a pentose structure are conjugated together in a linear chain or a branched chain, containing a lactated, sulfated sugar as a constituent, where 2.7 or more hydroxyl groups per 100 hydroxyl groups are sulfated or sulfur element occupies 1.5% by weight or more of all of the elements, in the sugar chain unit. A sugar derivative with a novel polysaccharide structure as derived from Aphanothece sacrum is provided in such manner.

Abstract: Described herein are methods for treating interstitial cystitis in a subject comprising administering to the subject an effective amount of a compound which is a modified hyaluronan or a pharmaceutically acceptable salt or ester thereof, wherein said hyaluronan or its pharmaceutically acceptable salt or ester comprises at least one sulfate group and the primary C-6 hydroxyl proton of at least one N-acetyl-glucosamine residue is substituted with an unsubstituted alkyl group or fluoroalkyl group.

Abstract: Provided herein are small molecule stimulators of neuronal growth, their preparation, and their use for treatment of neurological disorders. In one embodiment, provided herein are methods of treatment, prevention, or amelioration of a variety of medical conditions associated with neurological disorders using the compounds and compositions provided herein.

Abstract: An inhibiting heart failure disease pharmaceutical composition is provided. The pharmaceutical composition includes: an effective amount of a KMUP-3 amine salt of formula (I); wherein RX contains a carboxylic group donated from one selected from a group consisting of a sodium carboxyl methylcellulose (sodium CMC), a ?-polyglutamic acid derivative, and co-polymer salt; RX? is an anion form of the carboxylic group; and a pharmaceutically accepted carrier.

Abstract: Described herein are alkylated and semi-synthetic glycosaminoglycosan ethers, referred to herein as “SAGEs.” The synthesis of sulfated and alkylated SAGEs is also described. The compounds described herein are useful in a number of applications including use for ocular or ophthalmic treatment.

Abstract: Certain zwitterionic polysaccharides, including those naturally expressed by commensal B. fragilis in the gut, interact with cells of the immune system and affect the TH1/TH2 balance so as to promote health. Nutritional formulas and nutritional supplements containing isolated preparations of such zwitterionic polysaccharides, and methods for preparing the nutritional formulas and supplements, are provided. Also provided is a method of promoting immune system maturation in an infant involving enteral administration of a nutritional formula or nutritional supplement of the invention.

Abstract: Disclosed are polysaccharides containing residues of glucosamine or galactosamine in the repetitive unit, characterized by the presence of esters on the hydroxyls or amides on the amine functions, with lipoic acid or with mixtures of lipoic acid and formic acid.

Abstract: Inhibitors of parasitic dihydroorotate dehydrogenase enzyme (DHOD) are candidate therapeutics for treating malaria. Illustrative of such therapeutic agents include the compound: and a triazolopyrimidine class of compounds that conform to Formula IX: and their solvates, stereoisomers, tautomers and pharmaceutically acceptable salts.

Abstract: The present invention is a method of manufacturing an eye lens material having a process in which a phosphorylcholine group-containing chemical compound represented by the following formula (1) is reacted and covalently bonded to the surface of an eye lens material having hydroxyl groups wherein the chemical compound represented by the following formula (2) is reacted and covalently bonded through ester-bonding to the eye lens material in an organic solvent. The object of the present invention is to provide an eye lens material that prevents protein adsorption and a method of manufacturing thereof.

Abstract: A method for producing chitosan from naturally occurring chitin-containing raw material, such as crustacean shells, includes an optional pretreatment step to remove non-chitin rich organic material for example, shrimp flesh, from the raw material, e.g., shrimp shells. The optional pretreatment is followed by a demineralization step utilizing a mild hydrochloric acid solution and a deproteination step utilizing a mild sodium hydroxide solution. The deproteination step is followed by a deacetylation step to remove the acetyl group from N-acetylglucosamine (chitin) to form an amine group, yielding d-glucosamine (chitosan). Each step is followed by a washing step and the product is dried, preferably at a temperature not in excess of about 65° C. Known purification and grinding steps may also be used to produce the final chitosan product. The process is carried out in equipment comprising a series of substantially identical or similar tanks (18, 26, 36, etc.) and dryers (62, 62?), suitably interconnected.

Abstract: The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides TLR7 agonists and TLR7/TLR8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof. Derivatives of the imidazoquinoline derived compounds also include dendrimers and dimers of the imidazoquinoline derived compounds, and methods of making and using the dendrimeic and dimeric imidazoquinoline derived compounds. The present disclosure also provides dual TLR2/TLR7 hybrid agonists that include imidazoquinoline derived compounds of the present disclosure.

Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to methods of making nanostructures (e.g., nanoparticles, nanofibers), systems for making nanostructures, and the like.

Abstract: The present invention relates to immobilization compounds (I), immobilization products and preparations thereof as well as methods and uses for the identification of kinase interacting compounds or for the purification or identification of kinase proteins.

Abstract: Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.

Abstract: The method for manufacturing hyaluronic acid rich matrix comprises the steps of providing a crest; and decellularizing a tissue of crest to form a decellularized hyaluronic acid rich matrix.

Abstract: Branched end reactants having two or three functional groups at the ends are disclosed. The branched end reactants are used to prepare crosslinked hydrogel tissue adhesives, which have a good balance of mechanical properties in an aqueous environment. Kits comprising the branched end reactants and methods for applying a coating to an anatomical site on tissue of a living organism are also disclosed.

Abstract: The synthesized piperazium salt of KMUPs disclosed in the present invention is characterized by presented pharmaceutics having functions to improve 5-HT function and eNOS expression of KMUPS in lung diseases, such as proliferation, obliteration, pulmonary artery hypertension. The pharmaceutical composition for inhibiting monocrotaline (MCT)-induced proliferation of pulmonary artery includes an effective amount of a complex salt of formula (I): wherein R2 and R4 are each selected independently from the group consisting of a C1˜C5 alkoxy group, a hydrogen, a nitro group, and a halogen atom; RX contains a carboxylic group donated from one selected from a group consisting of a Statin, a Co-polymer, a poly-?-polyglutamic acid (?-PGA) derivative and sodium CMC; and ?RX substituent is an anion of the carboxylic group carrying a negative charge; and a pharmaceutically accepted carrier.

Abstract: A method for easily and efficiently separating a sialyllactose material from a milk material is disclosed. The method comprises removing proteins from the milk material to obtain a protein-free liquid, adjusting the pH of the protein-free liquid to obtain a pH-adjusted liquid, and concentrating the pH-adjusted liquid by an ultrafiltration (UF) membrane. Since the method also allows separation of sialyllactose from lactose and minerals, sialyllactose can be obtained with high purity, making the sialyllactose material highly useful for food, pharmaceutical, and other applications.

Abstract: The invention relates to pharmaceutical compositions with activity against disorders of urogenital system of mammals which comprises a zinc-hyaluronan complex as active ingredient and a pharmaceutically acceptable carrier and/or additive. The process for the preparation of said pharmaceutical compositions as well as the therapeutic use thereof for the treatment and prevention of diseases associated with abnormalities and deficiencies of glucosaminoglycan (GAG) layer in the urogenital system in mammals and a kit comprising zinc hyaluronate solution, a catheter which is applicable to intravesical administration and optionally a balloon which is applicable to bladder dillatation are also within the scope of the invention.

Abstract: The present invention relates to osteoblast derived glycosaminoglycan mixtures and to their use in one or more of: inhibition of osteoclastogenesis, enhancement of proliferation of osteoblasts, and/or the treatment or prevention of bone fracture or bone deterioration.

Abstract: A polymer having a structure according to the following formula (I): wherein: A represents a hydrophilic group; B represents a hydrophobic aromatic group such as 5-dimethylamino-1-naphthalenesulfonyl (Dansyl), 9-fluorenylmethoxy carbonyl (Fmoc) and naphthalene (Naphth); D and E independently represent amine groups; F represents an amine group, the amine group being substituted with a B group and an A group, or the amine group being a quaternary ammonium moiety; wherein W, X, Y and Z each independently have values greater than or equal to (1), especially in the range of (1) to (10).

Abstract: The invention relates to a method for preparing N-succinimidyl N-biotinyl-6-aminocaproate, characterised in that said method includes a step of activating N-biotinyl-6-aminocaproic acid in the form of a mixed anhydride, followed by coupling said mixed anhydride with N-hydroxysuccinimide.

Abstract: A sugar-anchor polymer and methods of making and using the same to stabilize a lipid membrane. The sugar-anchor polymer includes a sugar covalently bound to a first anchor and a second anchor wherein the covalent bonds are selected from the group consisting essentially of an oxime bond, a hydrazone bond, an acylhydrazide bond, an aminothioacetal bond, an acetal bond, a thioacetal bond, a dithioacetal bond, a thioether bond and combinations thereof. The method includes reacting a sugar having at least two nucleophilic moieties with at least two anchors, each anchor having at least one electrophilic moiety, to form the polymer. Alternatively, the method includes reacting a sugar having at least two electrophilic moieties with at least two anchors, each anchor having at least one nucleophilic moiety, to form the polymer. The anchors may be lipids or peptides. The sugar-anchor polymers stabilize lipid membranes against serum proteins, dehydration, and cryopreservation.

Abstract: Acid polysaccharides characterized by the concomitant presence of partial esters with non-polysaccharide carboxylic acids and esters between the acid groups of the initial polysaccharide and the alcohol groups of the repetitive units, with the formation of crosslinking among the polysaccharide chains.

Abstract: Preparation and use of synthetic trisaccharides useful for the preparation of synthetic heparinoids.

Abstract: The present invention is directed to compositions comprising a polymer backbone with protective chain and anionic groups, and a cationic therapeutic agent. The present invention is directed to compositions for treating infections, inflammatory diseases, excess growth, and damaged cells and organs.